William Allan Corp Acquires New Stake in Kenvue Inc. (NYSE:KVUE)

William Allan Corp acquired a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 37,859 shares of the company's stock, valued at approximately $876,000.

Other institutional investors have also recently bought and sold shares of the company. Riverview Trust Co bought a new stake in shares of Kenvue during the 3rd quarter worth approximately $30,000. Ashton Thomas Securities LLC bought a new stake in shares of Kenvue during the 3rd quarter worth $35,000. Deseret Mutual Benefit Administrators boosted its stake in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock valued at $45,000 after buying an additional 651 shares in the last quarter. Studio Investment Management LLC raised its stake in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock worth $45,000 after acquiring an additional 845 shares in the last quarter. Finally, Brooklyn Investment Group acquired a new position in Kenvue during the third quarter worth about $71,000. Institutional investors own 97.64% of the company's stock.

Kenvue Trading Down 0.2 %

Shares of NYSE:KVUE traded down $0.05 during midday trading on Friday, reaching $24.08. The company's stock had a trading volume of 7,516,534 shares, compared to its average volume of 17,823,225. The firm has a market capitalization of $46.17 billion, a price-to-earnings ratio of 43.87, a PEG ratio of 2.19 and a beta of 1.36. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The firm has a 50 day moving average price of $22.92 and a two-hundred day moving average price of $20.96. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same period in the previous year, the company posted $0.31 EPS. The firm's revenue was down .4% compared to the same quarter last year. As a group, analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.41%. The ex-dividend date was Wednesday, November 13th. Kenvue's payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Jefferies Financial Group assumed coverage on Kenvue in a research report on Tuesday, September 24th. They set a "buy" rating and a $27.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Piper Sandler boosted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a "neutral" rating in a research report on Monday, September 23rd. Finally, UBS Group lifted their target price on Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.